Tralokinumab (Adbry, Leo Pharma) provides stable long-term control of atopic dermatitis (AD), new research shows.
The new data, presented at the annual meeting of the American Academy of Dermatology in San Diego, CA, suggests that it’s possible to transition from flare-driven AD treatment with topical therapies to stable disease control with long-term tralokinumab treatment.
The new post hoc analysis included 347 adults with moderate-to-severe AD who were continuously treated with tralokinumab for 52 weeks in the phase 3 ECZTRA 1 and 2 trials and subsequently for up to 152 weeks in the ECZTEND open-label extension trial. Patients were permitted to enter ECZTEND after completion of the parent trial regardless of their treatment response or whether they were treated with Adbry or placebo.
More than 70% of patients who continued treatment with tralokinumab maintained stable Eczema Area and Severity Index (EASI) ≤7 at ≥80% of the days, and more than half of responders maintained stable EASI ≤7 at 100% of the days for up to three years, the study showed.
“Atopic dermatitis (AD) is a chronic disease requiring control over time. Ideally, medications for AD should have a durable effect, one that controls disease consistently over many years,” Andrew Blauvelt, MD, MBA, a dermatologist at Blauvelt Consulting, LLC, in Lake Oswego, U.S, tells TDD. “This study shows that tralokinumab controls AD over time, an ideal result for patients.”
The main take-away message? “Dermatology practitioners should have confidence in utilizing tralokinumab to help consistently control disease over time in their AD patients,” Dr. Blauvelt says.
